High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after
percutaneous coronary intervention (PCI). The introduction of more potent antiplatelet drugs …

High on-treatment platelet reactivity (HPR) by ADP, which primarily reflects the effect of
thienopyridines, has been found to be an independent predictor of ischemic events in …

Background On-treatment platelet reactivity to clopidogrel is variable and in part genetic
dependent. In African American (AA) patients, the relation between on-treatment platelet …

High platelet reactivity (HPR) after P2Y 12-inhibition in patients undergoing coronary
stenting is associated with an increased risk for thromboembolic events and coronary death …

INTRODUCTION: Information regarding any possible additional effect of genetic variants
other than CYP2C19* 2 on platelet reactivity in patients undergoing percutaneous coronary …

INTRODUCTION: High on-treatment platelet reactivity (HTPR) after clopidogrel loading dose
(LD) is associated with a high risk of thrombotic events after percutaneous coronary …

Dual antiplatelet therapy with aspirin and clopidogrel dramatically reduced the rate of major
adverse cardiac events following percutaneous coronary intervention. Clopidogrel is a …

Background High residual platelet reactivity in patients receiving clopidogrel is associated
with an increased risk of a cardiovascular event after coronary stenting. The aim of our study …

High on-clopidogrel platelet reactivity (HPR) associates with ischemic risk in patients after
percutaneous intervention (PCI). This study aimed to evaluate the association of HPR as …

Background The efficacy and safety of dual antithrombotic therapy (DAT) with oral
anticoagulant and P2Y12 inhibitors (P2Y12i) in patients with atrial fibrillation (AF) …